Stevanato Group (NYSE:STVN) shares hit a snag today despite third-quarter results that beat the consensus forecast.
The Piombino Dese, Italy-based drug delivery technology developer posted profits of $21.6 million, or 8¢ per share, on sales of $248.6 million for the three months ended Sept. 30, 2021, for a 12.5% bottom-line gain on sales growth of 36.5%.
Get the full story at our sister site, Drug Delivery Business News.